Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1986 1
1987 1
1989 1
1992 1
1997 2
1999 1
2002 1
2003 1
2007 1
2008 1
2009 1
2010 2
2011 2
2012 2
2013 1
2014 1
2015 4
2016 5
2017 3
2018 3
2019 2
2020 8
2021 5
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Peritoneal Malignant Mesothelioma"
Page 1
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators. Fennell DA, et al. Lancet Oncol. 2021 Nov;22(11):1530-1540. doi: 10.1016/S1470-2045(21)00471-X. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656227 Free PMC article. Clinical Trial.
BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. ...INTERPRETATION: Nivolumab represents a treatment that might be ben …
BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesot …
Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S, Arnaud A, Orbach D, Andre N, Berger C, Kepenekian V, Brigand C, Fresneau B, Poli-Merol ML, Habougit C, Varlet F, Scalabre A. Vermersch S, et al. Pediatr Blood Cancer. 2020 Jun;67(6):e28286. doi: 10.1002/pbc.28286. Epub 2020 Apr 11. Pediatr Blood Cancer. 2020. PMID: 32277799
METHODS: We performed a retrospective analysis of all identified children (< 18-year-old) treated in France from 1987 to 2017 for a diffuse malignant peritoneal mesothelioma (DMPM) or a multicystic peritoneal mesothelioma (MCPM). ...After a m …
METHODS: We performed a retrospective analysis of all identified children (< 18-year-old) treated in France from 1987 to 2017 for a diffu …
Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial.
Dietz MV, Quintelier KLA, van Kooten JP, de Boer NL, Vink M, Brandt-Kerkhof ARM, Verhoef C, Saeys Y, Aerts JGJV, Willemsen M, Van Gassen S, Madsen EVE. Dietz MV, et al. J Immunother Cancer. 2023 Aug;11(8):e007070. doi: 10.1136/jitc-2023-007070. J Immunother Cancer. 2023. PMID: 37536940 Free PMC article. Clinical Trial.
BACKGROUND: Malignant peritoneal mesothelioma (MPM) is an aggressive malignancy with a poor prognosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival outcomes, but recurrence rates remain high. Dendr …
BACKGROUND: Malignant peritoneal mesothelioma (MPM) is an aggressive malignancy with a poor prognosis. Cytoreductive su …
Multicystic peritoneal mesothelioma: A short review.
Zhang CH, Yu JW, Luo M. Zhang CH, et al. Curr Probl Cancer. 2017 Sep-Oct;41(5):340-348. doi: 10.1016/j.currproblcancer.2017.03.002. Epub 2017 Mar 31. Curr Probl Cancer. 2017. PMID: 28528021 Review.
Multicystic peritoneal mesothelioma (MCPM) is a rare neoplasm, predominantly affecting female patients during their reproductive years. ...Some authors consider it to be a reactive process for its association with prior surgery or abdominal inflammation. But its hig …
Multicystic peritoneal mesothelioma (MCPM) is a rare neoplasm, predominantly affecting female patients during their reproducti …
Preventing recurrence of diffuse malignant peritoneal mesothelioma.
Leinwand JC, Chabot JA, Kluger MD. Leinwand JC, et al. Expert Rev Anticancer Ther. 2016 Sep;16(9):989-95. doi: 10.1080/14737140.2016.1220305. Epub 2016 Aug 12. Expert Rev Anticancer Ther. 2016. PMID: 27486718 Review.
INTRODUCTION: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive malignancy with a poor prognosis when treated with systemic therapy. ...We assess the pharmacokinetics supporting the use of dwell IPC. We outline clinical, imaging and lab …
INTRODUCTION: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive malignancy with a poor prognosis when t …
Localized Malignant Peritoneal Mesothelioma (LMPeM) in Women: A Clinicopathologic Study of 18 Cases.
Malpica A, Euscher ED, Marques-Piubelli ML, Miranda RN, Raghav KP, Fournier KF, Ramalingam P. Malpica A, et al. Am J Surg Pathol. 2022 Oct 1;46(10):1352-1363. doi: 10.1097/PAS.0000000000001924. Epub 2022 Jun 20. Am J Surg Pathol. 2022. PMID: 35713639
Localized malignant peritoneal mesothelioma is a rare tumor with limited information in the literature. ...Seventy-seven percent had some form of abdominopelvic surgery and/or inflammatory process. Most cases had microscopic features typically seen in mali …
Localized malignant peritoneal mesothelioma is a rare tumor with limited information in the literature. ...Seventy-seve …
Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma.
Taghizadeh H, Zöchbauer-Müller S, Mader RM, Müllauer L, Klikovits T, Bachleitner-Hofmann T, Hoda MA, Prager GW. Taghizadeh H, et al. Thorac Cancer. 2020 Jul;11(7):1979-1988. doi: 10.1111/1759-7714.13491. Epub 2020 May 21. Thorac Cancer. 2020. PMID: 32438515 Free PMC article. Clinical Trial.
BACKGROUND: Malignant mesothelioma is an aggressive cancer and has a poor prognosis. Here, we analyzed the feasibility, molecular and gender aspects of targeted therapy recommendations for malignant mesothelioma based on the individual molecular tumor …
BACKGROUND: Malignant mesothelioma is an aggressive cancer and has a poor prognosis. Here, we analyzed the feasibility, molecu …
Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
Deban M, Taqi K, Knapp GC, Soucisse M, Curry M, Sidéris L, Dubé P, Khaldi MA, Jedrzejko N, Porter G, Giacomantonio C, Hamilton T, MacNeill A, Mack L, Bouchard-Fortier A. Deban M, et al. J Surg Oncol. 2023 Sep;128(4):595-603. doi: 10.1002/jso.27301. Epub 2023 May 30. J Surg Oncol. 2023. PMID: 37249154
INTRODUCTION: Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. ...METHODS: A multicenter retrospective study was performed on patients diagnosed and treated for PM with CRS and HIPEC in four major peritoneal dis …
INTRODUCTION: Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. ...METHODS: A m …
Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy.
Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M. Sugarbaker PH, et al. J Oncol Pract. 2016 Oct;12(10):928-935. doi: 10.1200/JOP.2016.011908. J Oncol Pract. 2016. PMID: 27858561
Malignant peritoneal mesothelioma is a rare disease, with approximately 800 new patients per year in the United States. ...This management plan should be considered the standard of care for properly selected patients with malignant peritoneal …
Malignant peritoneal mesothelioma is a rare disease, with approximately 800 new patients per year in the United States. …
Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
Belfiore A, Busico A, Bozzi F, Brich S, Dallera E, Conca E, Capone I, Gloghini A, Volpi CC, Cabras AD, Pilotti S, Baratti D, Guaglio M, Deraco M, Kusamura S, Perrone F. Belfiore A, et al. Int J Mol Sci. 2019 Nov 19;20(22):5817. doi: 10.3390/ijms20225817. Int J Mol Sci. 2019. PMID: 31752449 Free PMC article.
Background-There are currently no effective therapies for diffuse malignant peritoneal mesothelioma (DMPM) patients with disease recurrence. ...Conclusion-The results indicate that the coordinated activity of multiple cross-talks between RTKs is direct …
Background-There are currently no effective therapies for diffuse malignant peritoneal mesothelioma (DMPM) patients wit …
52 results